

pBOOST4-mcs

Negative control plasmid for the pBOOST4 vaccine adjuvant plasmid

Catalog code: pbst4-mcs

<https://www.invivogen.com/pboost-control>

For research use only

Version 21F29-MM

PRODUCT INFORMATION

Contents

- 20 µg of pBOOST4-mcs provided as lyophilized DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pBOOST4 plasmids were developed as genetic adjuvants for DNA vaccines to potentiate the immune response to a specific antigen. They contain two transcription units allowing the co-expression of two cytokine genes that promote dendritic cell development. These plasmids feature two strong composite promoters derived from the ferritin light chain (FerL) and heavy chain (FerH) core promoters. Both promoters work concomitantly to express ferritin, a ubiquitous protein, therefore, eliminating potential transcription interference. pBOOST4-mcs expresses two multiple cloning sites (MCS). It can be used as a negative control or as a cloning vector.

PLASMID FEATURES

- **MCS1 includes the following restriction sites: Agel, EcoRV, BamHI, Sall and AvrII**
 - Agel is compatible with BspEI and SgrAI
 - EcoRV is compatible with any blunt-end restriction enzymes
 - BamHI is compatible with BglIII, BstYI and BclI
 - Sall is compatible with Aval and XhoI
 - AvrII is compatible with XbaI, SpeI and NheI
- **MCS2 includes the following restriction sites: SgrAI, BglIII, XhoI and NheI**
 - SgrAI is compatible with BspEI and Agel
 - BglIII is compatible with BamHI, BstYI and BclI
 - XhoI is compatible with Aval and Sall
 - NheI is compatible with XbaI, SpeI and AvrII

- **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein¹. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.
- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids².
- **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (hCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The hCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer³.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*⁴
- **ori pMB1:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.
- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression⁵.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic Blasticidin. In bacteria, *bsr* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *bsr* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES.
- **hEF1a pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com



METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

Intramuscular inoculation

The plasmid pBOOST4-mcs can be used as negative control together with pBOOST4-mFLT3L-mGMCSF, a genetic adjuvant for DNA vaccines featuring the murine mFLT3L and GM-CSF genes.

For more information, visit <https://www.invivogen.com/pboost>.

Plasmid DNA solution

1. Prepare the vaccine plasmid solution by resuspending 10 µg of the vaccine plasmid DNA in 50 µl saline solution.

2. Prepare the pBOOST4 solution by mixing 10 µg of pBOOST4-mFLT3L-mGMCSF and 90 µg of the mock plasmid pBOOST4-mcs in 50 µl saline solution for low dose, or 100 µg of pBOOST4-mFLT3L-mGMCSF in 50 µl saline solution for high dose.

Note: Use the negative control pBOOST4-mcs at the same concentration as pBOOST4-mFLT3L-mGMCSF.

3. Combine both solutions to obtain a total of 110 µg DNA in 100 µl saline solution.

Note: The quantities are per mouse.

Intramuscular injections

1. Inoculate 6 to 8-week old female BALB/c mice with 100 µl plasmid DNA solution (described above) into the quadriceps at 0 and 4 weeks.

2. Collect sera and analyze for antibodies at 8 weeks.

RELATED PRODUCTS

Product	Description	Cat.Code
Blasticidin	Selection antibiotic	ant-bl-1
ChemiComp GT116	Competent <i>E. coli</i>	gt116-11
pBOOST4-mFLT3L-mGMCSF	Genetic adjuvant	pbst4-mf3csf2

REFERENCES

1. Eisenstein RS. & Munro H.N. 1990. Translational regulation of ferritin synthesis by iron. *Enzyme* 44(1-4):42-58.
2. Dean D.A. *et al.*, 1999. Sequence requirements for plasmid nuclear import. *Exp. Cell. Res.* 253:713-22.
3. Boshart M. *et al.*, 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 141(2):521-30.
4. Carswell S. & Alwine J.C. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
5. Ramesh N. *et al.*, 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. *Nucleic Acids Res.* 24(14):2697-700.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: info@invivogen.com



1 CTGCAGGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAA
101 CGCCAATAGGGACTTTCATTGACGTCAATGGGTGGAGTATTACGGTAAACTGCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCC
201 TATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATC
301 GCTATTACCATGATGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTCCAAGTCTCCACCCATTGACGTCAATG
401 GGAGTTTGTTTTGACTAGTCAGGGCCCAACCCCCCAAGCCCCATTTCACAACACGCTGGCGCTACAGGCGGTGACTTCCCTTGCTTTGGGGCGGG
501 GGGCTGAGACTCTATGTGCTCCGATTGGTCAGGCACGGCCTTCGGCCCGCCTCTGCCACCGCAGATTGGCCGCTAGGCCTCCCCGAGCGCCTGCC
601 TCCGAGGGCCGGCGACCATAAAGAAGCCGCCCTAGCCACGTCCCCTCGAGTTCGGCGGTCCCGGGTGTGTCTCAAGCTTGGCCGAGAACACAGg
701 taagtgccgtgtgtggttcccgcgggcctggcctctttacgggttatggccttgcgtgccttgaattacttccatgcccctggctgcagtacgtgatc
801 ttgatcccagccttcgggttgaagtgggtgggagagtgcaggccttgcgcttaaggagccccttcgctcgtgcttgagttgaggcctggcttggcg
901 ctggggccgcccgtgctaactcgttggcaccttcgcccctgtctcgtgcttctcgttaagtctctagccattaaaatthttgataaccagctgcgagc
1001 cttttttctgpcgagatagcttctaataatgcccagatctgcacactggtatctcggtttttggggccgcccggcgagcgggcccgtgctccc
1101 agcgcacatgttcggcgaggcggggcctgcgagcgcggccaccgagaatcggagcgggtagtctcaactggccggcctgctcgtgctggcctgc
1201 gccgccgtgtatcggccgctgggcccaggtggcccggcggcaccagttgcgtgagcggaaagatggccgcttcccggccctgctgcagggagc
1301 tcaaatggaggacgcccgggagagcgggcccgggtgagtcaccacacaaagaaaaggccttccctcctcatccgtcgttcatgtgactcca
1401 cggagtaccgggcccgtccaggcacctcgattagttgctgagcttttgagtagctcgtccttaggttgggggaggggtttatgcatggagttcc
1501 ccacactgagtggtggagactgaagagttaggccagcttggcacttgatgtaattccttgggaatttggcctttttgagtttggatcttgcctcattc
1601 tcaagcctcagacagtggttcaagttttttcttccatttcagGTGTCGTGAAAAC TACCCCTAAAAGCCACCGGCGTGC GCAAGATCTGAATTCTTCG
NheI (1708) SgrAI (1670) FspI (1678) BglIII (1684) BstBI (1696)
XhoI (1702)
1701 AACTCGAGGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGACAAACCACAAC TAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTG
1801 TGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCCAGGGGAGGTGTGG
1901 GAGGTTTTTTAAAGCAAGTAAACCTCTACAAATGTGGTATGAAATGTTAATTAAGTACCATGACCAAATCCCTTAACGTGAGTTTTTCGTTCCACTG
2001 AGCGTCAGACCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGGTAATCTGCTGCTTGCAAACAAAAAACCACCGCTACCAGCG
2101 GTGGTTTTTTGCCGATCAAGAGCTACCAACTCTTTTCCGAAGGTAAGTGGCTTACGAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGT
2201 AGTTAGGCCACCATTCAAGAACTCTGTAGCACCGCTACATACCTCGCTCTGCTAATCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCT
2301 TACCGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGTTCTGTGCACACAGCCAGCTTGAGCGAACGACCTAC
2401 ACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGGCCACGCTTCCGAAGGGAGAAAGCGGACAGGTATCCGGTAAGCGGACGGGTCCGGAACAG
2501 GAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTATCTTTATAGTCTGTCCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTC
2601 GTCAGGGGGCGGAGCCTATGAAAAACGCCAGCAACGCGCCTTTTACGGTTCCTGGCCTTTTGTGCTGCTTTTGTGCTCACATGTTCTTAATTAACCTG
2701 CAGGGCTGAAATAACCTCTGAAAGAGGAACCTGGTTAGGTACCTTCTGAGGCTGAAAGAACCAGCTGTGGAATGTGTGTCAGTTAGGGTGTGAAAGTC
2801 CCCAGGCTCCCCAGCAGGAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGAAAGTCCCAGGCTCCCCAGCAGGCAGAAGTATG
2901 CAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCACTAGTTCGCCAGAGCGCGAGGGCCTCCAGCGGCCGCCCTCCCCACAGCAGGGGCGG
3001 GGTCCCGGCCACCAGGAGCGGGCTCGGGCGGGCGGCCTGATTGGCCGGGCGGGCCTGACGCCGACGGGCTATAAGAGACCACAAGCGACCC
3101 GCAGGGCCAGACGTTCTTCGCCGAAGCTTGCCGTCAGAACGCAGGTGAGGGGCGGGTGTGGCTTCCGCGGGCCGCCGAGCTGGAGTCTGCTCCGAGCG

